{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T09:59:36Z","timestamp":1791885576938,"version":"4.3.4"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MOP-126139"],"award-info":[{"award-number":["MOP-126139"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"name":"American College of Gastroenterology Bridge Award"},{"DOI":"10.13039\/501100000264","name":"Canadian Liver Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000264","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Microbiome"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a range of histological findings from the generally benign simple steatosis to steatohepatitis (MASH) which can progress to fibrosis and cirrhosis. Several factors, including the microbiome, may contribute to disease progression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Here, we demonstrate links between the presence and abundance of specific bacteria in the adipose and liver tissues, inflammatory genes, immune cell responses, and disease severity. Overall, in MASLD patients, we observed a generalized obesity-induced translocation of gut bacteria to hepatic and adipose tissues. We identified microbial patterns unique to more severely diseased tissues. Specifically, <jats:italic>Enterococcus<\/jats:italic>, <jats:italic>Granulicatella<\/jats:italic>, and Morganellaceae abundance is positively correlated with immune cell counts and inflammatory gene expression levels, and both genera are significantly enriched in MASH patients. <jats:italic>Brevibacterium<\/jats:italic> is enriched in adipose tissues of patients with liver fibrosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Together, these results provide further insight into the microbial factors that may be driving disease severity.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40168-024-02004-7","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T08:10:25Z","timestamp":1736842225000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Characterization of liver, adipose, and fecal microbiome in obese patients with MASLD: links with disease severity and metabolic dysfunction parameters"],"prefix":"10.1186","volume":"13","author":[{"given":"Katherine J. P.","family":"Schwenger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia K.","family":"Copeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasaman","family":"Ghorbani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena M.","family":"Comelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Guttman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra E.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy D.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Okrainec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johane P.","family":"Allard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,14]]},"reference":[{"key":"2004_CR1","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1097\/hep.0000000000000670","volume":"79","author":"F Kanwal","year":"2024","unstructured":"Kanwal F, Neuschwander-Tetri BA, Loomba R, Rinella ME. Metabolic dysfunction-associated steatotic liver disease: update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease. Hepatology. 2024;79:1212\u20139. https:\/\/doi.org\/10.1097\/hep.0000000000000670.","journal-title":"Hepatology"},{"key":"2004_CR2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/ueg2.12525","volume":"12","author":"J Zeng","year":"2024","unstructured":"Zeng J, Fan JG, Francque SM. Therapeutic management of metabolic dysfunction associated steatotic liver disease. United European Gastroenterol J. 2024;12:177\u201386. https:\/\/doi.org\/10.1002\/ueg2.12525.","journal-title":"United European Gastroenterol J"},{"key":"2004_CR3","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1053\/j.gastro.2011.06.061","volume":"141","author":"MR Charlton","year":"2011","unstructured":"Charlton MR, et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011;141:1249\u201353. https:\/\/doi.org\/10.1053\/j.gastro.2011.06.061.","journal-title":"Gastroenterology"},{"key":"2004_CR4","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/nrgastro.2016.3","volume":"13","author":"ME Rinella","year":"2016","unstructured":"Rinella ME, Sanyal AJ. Management of NAFLD: a stage-based approach. Nat Rev Gastroenterol Hepatol. 2016;13:196\u2013205. https:\/\/doi.org\/10.1038\/nrgastro.2016.3.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2004_CR5","doi-asserted-by":"publisher","first-page":"104821","DOI":"10.1016\/j.ebiom.2023.104821","volume":"97","author":"L Crudele","year":"2023","unstructured":"Crudele L, Gadaleta RM, Cariello M, Moschetta A. Gut microbiota in the pathogenesis and therapeutic approaches of diabetes. EBioMedicine. 2023;97: 104821. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104821.","journal-title":"EBioMedicine"},{"key":"2004_CR6","doi-asserted-by":"publisher","first-page":"2304157","DOI":"10.1080\/19490976.2024.2304157","volume":"16","author":"R Forlano","year":"2024","unstructured":"Forlano R, et al. Disruption of gut barrier integrity and host\u2013microbiome interactions underlie MASLD severity in patients with type-2 diabetes mellitus. Gut Microbes. 2024;16:2304157. https:\/\/doi.org\/10.1080\/19490976.2024.2304157.","journal-title":"Gut Microbes"},{"key":"2004_CR7","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41575-018-0031-8","volume":"15","author":"A Tripathi","year":"2018","unstructured":"Tripathi A, et al. Publisher correction: the gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 2018;15:785. https:\/\/doi.org\/10.1038\/s41575-018-0031-8.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2004_CR8","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1111\/trf.13477","volume":"56","author":"S Paisse","year":"2016","unstructured":"Paisse S, et al. Comprehensive description of blood microbiome from healthy donors assessed by 16S targeted metagenomic sequencing. Transfusion. 2016;56:1138\u201347. https:\/\/doi.org\/10.1111\/trf.13477.","journal-title":"Transfusion"},{"key":"2004_CR9","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/s42255-020-0178-9","volume":"2","author":"FF Anhe","year":"2020","unstructured":"Anhe FF, et al. Type 2 diabetes influences bacterial tissue compartmentalisation in human obesity. Nat Metab. 2020;2:233\u201342. https:\/\/doi.org\/10.1038\/s42255-020-0178-9.","journal-title":"Nat Metab"},{"key":"2004_CR10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/B978-0-12-410524-9.00003-7","volume":"117","author":"J Henao-Mejia","year":"2013","unstructured":"Henao-Mejia J, Elinav E, Thaiss CA, Flavell RA. The intestinal microbiota in chronic liver disease. Adv Immunol. 2013;117:73\u201397. https:\/\/doi.org\/10.1016\/B978-0-12-410524-9.00003-7.","journal-title":"Adv Immunol"},{"key":"2004_CR11","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1136\/gutjnl-2019-318811","volume":"69","author":"S Sookoian","year":"2020","unstructured":"Sookoian S, et al. Intrahepatic bacterial metataxonomic signature in non-alcoholic fatty liver disease. Gut. 2020;69:1483\u201391. https:\/\/doi.org\/10.1136\/gutjnl-2019-318811.","journal-title":"Gut"},{"key":"2004_CR12","doi-asserted-by":"publisher","first-page":"e00182","DOI":"10.1097\/HC9.0000000000000182","volume":"7","author":"M Effenberger","year":"2023","unstructured":"Effenberger M, et al. A gut bacterial signature in blood and liver tissue characterizes cirrhosis and hepatocellular carcinoma. Hepatol Commun. 2023;7:e00182. https:\/\/doi.org\/10.1097\/HC9.0000000000000182.","journal-title":"Hepatol Commun."},{"key":"2004_CR13","doi-asserted-by":"publisher","first-page":"e151725","DOI":"10.1172\/JCI151725","volume":"132","author":"JC Leinwand","year":"2022","unstructured":"Leinwand JC, et al. Intrahepatic microbes govern liver immunity by programming NKT cells. J Clin Invest. 2022;132:e151725. https:\/\/doi.org\/10.1172\/JCI151725.","journal-title":"J Clin Invest."},{"key":"2004_CR14","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.3892\/ijmm.2018.3800","volume":"42","author":"KJP Schwenger","year":"2018","unstructured":"Schwenger KJP, et al. Markers of activated inflammatory cells are associated with disease severity and intestinal microbiota in adults with non-alcoholic fatty liver disease. Int J Mol Med. 2018;42:2229\u201337. https:\/\/doi.org\/10.3892\/ijmm.2018.3800.","journal-title":"Int J Mol Med"},{"key":"2004_CR15","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1038\/s41591-018-0169-5","volume":"24","author":"L Hoyles","year":"2018","unstructured":"Hoyles L, et al. Publisher correction: molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women. Nat Med. 2018;24:1628. https:\/\/doi.org\/10.1038\/s41591-018-0169-5.","journal-title":"Nat Med"},{"key":"2004_CR16","doi-asserted-by":"publisher","first-page":"e00466","DOI":"10.14309\/ctg.0000000000000466","volume":"13","author":"P Pettinelli","year":"2022","unstructured":"Pettinelli P, et al. Relationship between hepatic gene expression, intestinal microbiota, and inferred functional metagenomic analysis in NAFLD. Clin Transl Gastroenterol. 2022;13: e00466. https:\/\/doi.org\/10.14309\/ctg.0000000000000466.","journal-title":"Clin Transl Gastroenterol"},{"key":"2004_CR17","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1136\/gutjnl-2019-320118","volume":"69","author":"L Massier","year":"2020","unstructured":"Massier L, et al. Adipose tissue derived bacteria are associated with inflammation in obesity and type 2 diabetes. Gut. 2020;69:1796\u2013806. https:\/\/doi.org\/10.1136\/gutjnl-2019-320118.","journal-title":"Gut"},{"key":"2004_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3803\/EnM.2018.33.1.33","volume":"33","author":"C Boutari","year":"2018","unstructured":"Boutari C, Perakakis N, Mantzoros CS. Association of adipokines with development and progression of nonalcoholic fatty liver disease. Endocrinol Metab (Seoul). 2018;33:33\u201343. https:\/\/doi.org\/10.3803\/EnM.2018.33.1.33.","journal-title":"Endocrinol Metab (Seoul)"},{"key":"2004_CR19","doi-asserted-by":"publisher","first-page":"4153","DOI":"10.1113\/jphysiol.2009.174136","volume":"587","author":"PJ Turnbaugh","year":"2009","unstructured":"Turnbaugh PJ, Gordon JI. The core gut microbiome, energy balance and obesity. J Physiol. 2009;587:4153\u20138. https:\/\/doi.org\/10.1113\/jphysiol.2009.174136.","journal-title":"J Physiol"},{"key":"2004_CR20","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1007\/s11695-023-06679-z","volume":"33","author":"SH Keshavjee","year":"2023","unstructured":"Keshavjee SH, et al. Adipose tissue and plasma markers associated with HbA1c pre- and post-bariatric surgery: a cross-sectional and cohort study. Obes Surg. 2023;33:2443\u201351. https:\/\/doi.org\/10.1007\/s11695-023-06679-z.","journal-title":"Obes Surg"},{"key":"2004_CR21","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1053\/j.gastro.2019.12.054","volume":"158","author":"V Azzu","year":"2020","unstructured":"Azzu V, Vacca M, Virtue S, Allison M, Vidal-Puig A. Adipose tissue-liver cross talk in the control of whole-body metabolism: implications in nonalcoholic fatty liver disease. Gastroenterology. 2020;158:1899\u2013912. https:\/\/doi.org\/10.1053\/j.gastro.2019.12.054.","journal-title":"Gastroenterology"},{"key":"2004_CR22","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1111\/j.1572-0241.1999.01377.x","volume":"94","author":"EM Brunt","year":"1999","unstructured":"Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467\u201374. https:\/\/doi.org\/10.1111\/j.1572-0241.1999.01377.x.","journal-title":"Am J Gastroenterol"},{"key":"2004_CR23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nature08821","volume":"464","author":"J Qin","year":"2010","unstructured":"Qin J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464:59\u201365. https:\/\/doi.org\/10.1038\/nature08821.","journal-title":"Nature"},{"key":"2004_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/19490976.2021.1902705","volume":"13","author":"JK Copeland","year":"2021","unstructured":"Copeland JK, et al. The impact of migration on the gut metagenome of South Asian Canadians. Gut Microbes. 2021;13:1\u201329. https:\/\/doi.org\/10.1080\/19490976.2021.1902705.","journal-title":"Gut Microbes"},{"key":"2004_CR25","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/bcpt.13190","volume":"124","author":"J Skat-Rordam","year":"2019","unstructured":"Skat-Rordam J, Hojland Ipsen D, Lykkesfeldt J, Tveden-Nyborg PA. role of peroxisome proliferator-activated receptor gamma in non-alcoholic fatty liver disease. Basic Clin Pharmacol Toxicol. 2019;124:528\u201337. https:\/\/doi.org\/10.1111\/bcpt.13190.","journal-title":"Basic Clin Pharmacol Toxicol."},{"key":"2004_CR26","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.pharmthera.2016.07.015","volume":"167","author":"M Pruenster","year":"2016","unstructured":"Pruenster M, Vogl T, Roth J, Sperandio M. S100A8\/A9: from basic science to clinical application. Pharmacol Ther. 2016;167:120\u201331. https:\/\/doi.org\/10.1016\/j.pharmthera.2016.07.015.","journal-title":"Pharmacol Ther"},{"issue":"Suppl 1","key":"2004_CR27","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/j.jcjd.2017.10.003","volume":"42","author":"Z Punthakee","year":"2018","unstructured":"Punthakee Z, Goldenberg R, Katz P. Definition, classification and diagnosis of diabetes, prediabetes and metabolic syndrome. Can J Diabetes. 2018;42(Suppl 1):S10-s15. https:\/\/doi.org\/10.1016\/j.jcjd.2017.10.003.","journal-title":"Can J Diabetes"},{"key":"2004_CR28","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40168-016-0175-0","volume":"4","author":"F Stammler","year":"2016","unstructured":"Stammler F, et al. Adjusting microbiome profiles for differences in microbial load by spike-in bacteria. Microbiome. 2016;4:28. https:\/\/doi.org\/10.1186\/s40168-016-0175-0.","journal-title":"Microbiome"},{"key":"2004_CR29","doi-asserted-by":"publisher","first-page":"1038120","DOI":"10.3389\/fmicb.2022.1038120","volume":"13","author":"P Rajar","year":"2022","unstructured":"Rajar P, et al. Microbial DNA extraction of high-host content and low biomass samples: Optimized protocol for nasopharynx metagenomic studies. Front Microbiol. 2022;13:1038120. https:\/\/doi.org\/10.3389\/fmicb.2022.1038120.","journal-title":"Front Microbiol"},{"key":"2004_CR30","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12915-014-0087-z","volume":"12","author":"SJ Salter","year":"2014","unstructured":"Salter SJ, et al. Reagent and laboratory contamination can critically impact sequence-based microbiome analyses. BMC Biol. 2014;12:87. https:\/\/doi.org\/10.1186\/s12915-014-0087-z.","journal-title":"BMC Biol"},{"key":"2004_CR31","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13099-016-0103-7","volume":"8","author":"A Glassing","year":"2016","unstructured":"Glassing A, Dowd SE, Galandiuk S, Davis B, Chiodini RJ. Inherent bacterial DNA contamination of extraction and sequencing reagents may affect interpretation of microbiota in low bacterial biomass samples. Gut Pathog. 2016;8:24. https:\/\/doi.org\/10.1186\/s13099-016-0103-7.","journal-title":"Gut Pathog"},{"key":"2004_CR32","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/joim.13137","volume":"288","author":"AS Meijnikman","year":"2020","unstructured":"Meijnikman AS, et al. Distinct differences in gut microbial composition and functional potential from lean to morbidly obese subjects. J Intern Med. 2020;288:699\u2013710. https:\/\/doi.org\/10.1111\/joim.13137.","journal-title":"J Intern Med"},{"key":"2004_CR33","doi-asserted-by":"publisher","first-page":"1965463","DOI":"10.1080\/19490976.2021.1965463","volume":"13","author":"MAJ Hullar","year":"2021","unstructured":"Hullar MAJ, et al. Associations of the gut microbiome with hepatic adiposity in the Multiethnic Cohort Adiposity Phenotype Study. Gut Microbes. 2021;13:1965463. https:\/\/doi.org\/10.1080\/19490976.2021.1965463.","journal-title":"Gut Microbes"},{"key":"2004_CR34","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1136\/gutjnl-2018-316307","volume":"68","author":"H Chu","year":"2019","unstructured":"Chu H, Duan Y, Yang L, Schnabl B. Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease. Gut. 2019;68:359\u201370. https:\/\/doi.org\/10.1136\/gutjnl-2018-316307.","journal-title":"Gut"},{"key":"2004_CR35","doi-asserted-by":"publisher","first-page":"e1002533","DOI":"10.1371\/journal.pbio.1002533","volume":"14","author":"R Sender","year":"2016","unstructured":"Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol. 2016;14:e1002533. https:\/\/doi.org\/10.1371\/journal.pbio.1002533.","journal-title":"PLoS Biol."},{"key":"2004_CR36","doi-asserted-by":"publisher","first-page":"e0170034","DOI":"10.1371\/journal.pone.0170034","volume":"12","author":"S Vrakas","year":"2017","unstructured":"Vrakas S, et al. Intestinal bacteria composition and translocation of bacteria in inflammatory bowel disease. PLoS ONE. 2017;12:e0170034. https:\/\/doi.org\/10.1371\/journal.pone.0170034.","journal-title":"PLoS ONE."},{"key":"2004_CR37","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1136\/gutjnl-2019-318601","volume":"69","author":"BVH Hornung","year":"2020","unstructured":"Hornung BVH, Zwittink RD, Ducarmon QR, Kuijper E, Response J, to: \u2018Circulating microbiome in blood of different circulatory compartments\u2019 by Schierwagen, et al. Gut. 2020;69:789\u201390. https:\/\/doi.org\/10.1136\/gutjnl-2019-318601.","journal-title":"Gut"},{"key":"2004_CR38","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1136\/gutjnl-2019-319123","volume":"69","author":"R Schierwagen","year":"2020","unstructured":"Schierwagen R, et al. Trust is good, control is better: technical considerations in blood microbiome analysis. Gut. 2020;69:1362\u20133. https:\/\/doi.org\/10.1136\/gutjnl-2019-319123.","journal-title":"Gut"},{"key":"2004_CR39","doi-asserted-by":"publisher","first-page":"fiz045","DOI":"10.1093\/femsec\/fiz045","volume":"95","author":"BVH Hornung","year":"2019","unstructured":"Hornung BVH, Zwittink RD, Kuijper EJ. Issues and current standards of controls in microbiome research. FEMS Microbiol Ecol. 2019;95:fiz045. https:\/\/doi.org\/10.1093\/femsec\/fiz045.","journal-title":"FEMS Microbiol Ecol."},{"key":"2004_CR40","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s40168-017-0267-5","volume":"5","author":"D Kim","year":"2017","unstructured":"Kim D, et al. Optimizing methods and dodging pitfalls in microbiome research. Microbiome. 2017;5:52. https:\/\/doi.org\/10.1186\/s40168-017-0267-5.","journal-title":"Microbiome"},{"key":"2004_CR41","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/j.celrep.2019.01.091","volume":"26","author":"MT Nelson","year":"2019","unstructured":"Nelson MT, et al. Human and extracellular DNA depletion for metagenomic analysis of complex clinical infection samples yields optimized viable microbiome profiles. Cell Rep. 2019;26:2227-2240 e2225. https:\/\/doi.org\/10.1016\/j.celrep.2019.01.091.","journal-title":"Cell Rep."},{"key":"2004_CR42","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1097\/MCG.0b013e31827b4f94","volume":"47","author":"RJ Chiodini","year":"2013","unstructured":"Chiodini RJ, et al. Crohn\u2019s disease may be differentiated into 2 distinct biotypes based on the detection of bacterial genomic sequences and virulence genes within submucosal tissues. J Clin Gastroenterol. 2013;47:612\u201320. https:\/\/doi.org\/10.1097\/MCG.0b013e31827b4f94.","journal-title":"J Clin Gastroenterol"},{"key":"2004_CR43","doi-asserted-by":"publisher","first-page":"105856","DOI":"10.1016\/j.mimet.2020.105856","volume":"170","author":"FS Heravi","year":"2020","unstructured":"Heravi FS, Zakrzewski M, Vickery K, Hu H. Host DNA depletion efficiency of microbiome DNA enrichment methods in infected tissue samples. J Microbiol Methods. 2020;170:105856. https:\/\/doi.org\/10.1016\/j.mimet.2020.105856.","journal-title":"J Microbiol Methods"},{"key":"2004_CR44","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nature24621","volume":"551","author":"LR Thompson","year":"2017","unstructured":"Thompson LR, et al. A communal catalogue reveals Earth\u2019s multiscale microbial diversity. Nature. 2017;551:457\u201363. https:\/\/doi.org\/10.1038\/nature24621.","journal-title":"Nature"},{"key":"2004_CR45","doi-asserted-by":"publisher","first-page":"1129904","DOI":"10.3389\/fmicb.2023.1129904","volume":"14","author":"SJ Yoon","year":"2023","unstructured":"Yoon SJ, et al. Bifidobacterium-derived short-chain fatty acids and indole compounds attenuate nonalcoholic fatty liver disease by modulating gut-liver axis. Front Microbiol. 2023;14:1129904. https:\/\/doi.org\/10.3389\/fmicb.2023.1129904.","journal-title":"Front Microbiol"},{"key":"2004_CR46","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/hep.28356","volume":"63","author":"J Boursier","year":"2016","unstructured":"Boursier J, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016;63:764\u201375. https:\/\/doi.org\/10.1002\/hep.28356.","journal-title":"Hepatology"},{"key":"2004_CR47","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/odi.12191","volume":"20","author":"S Naka","year":"2014","unstructured":"Naka S, et al. A specific Streptococcus mutans strain aggravates non-alcoholic fatty liver disease. Oral Dis. 2014;20:700\u20136. https:\/\/doi.org\/10.1111\/odi.12191.","journal-title":"Oral Dis"},{"key":"2004_CR48","doi-asserted-by":"publisher","first-page":"649060","DOI":"10.3389\/fcimb.2021.649060","volume":"11","author":"X Zhong","year":"2021","unstructured":"Zhong X, et al. Streptococcus, the predominant bacterium to predict the severity of liver injury in alcoholic liver disease. Front Cell Infect Microbiol. 2021;11:649060. https:\/\/doi.org\/10.3389\/fcimb.2021.649060.","journal-title":"Front Cell Infect Microbiol."},{"key":"2004_CR49","doi-asserted-by":"publisher","first-page":"728823","DOI":"10.3389\/fmicb.2021.728823","volume":"12","author":"T Wang","year":"2021","unstructured":"Wang T, Guo XK, Xu H. Disentangling the progression of non-alcoholic fatty liver disease in the human gut microbiota. Front Microbiol. 2021;12: 728823. https:\/\/doi.org\/10.3389\/fmicb.2021.728823.","journal-title":"Front Microbiol"},{"key":"2004_CR50","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.3390\/microorganisms11122999","volume":"11","author":"GH Hizo","year":"2023","unstructured":"Hizo GH, Rampelotto PH. The role of bifidobacterium in liver diseases: a systematic review of next-generation sequencing studies. Microorganisms. 2023;11:2999. https:\/\/doi.org\/10.3390\/microorganisms11122999.","journal-title":"Microorganisms."},{"key":"2004_CR51","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3390\/fermentation9040395","volume":"9","author":"M Monserrat-Mesquida","year":"2023","unstructured":"Monserrat-Mesquida M, Bouzas C, Mascar\u00f3 CM, Tejada S, Sureda A. Probiotics as potential therapy in the management of non-alcoholic fatty liver disease (NAFLD). Fermentation. 2023;9:395.","journal-title":"Fermentation"},{"key":"2004_CR52","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.micres.2016.07.001","volume":"192","author":"A Sarkar","year":"2016","unstructured":"Sarkar A, Mandal S. Bifidobacteria-Insight into clinical outcomes and mechanisms of its probiotic action. Microbiol Res. 2016;192:159\u201371. https:\/\/doi.org\/10.1016\/j.micres.2016.07.001.","journal-title":"Microbiol Res"},{"key":"2004_CR53","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.3389\/fmicb.2017.02345","volume":"8","author":"L Ruiz","year":"2017","unstructured":"Ruiz L, Delgado S, Ruas-Madiedo P, Sanchez B, Margolles A. Bifidobacteria and their molecular communication with the immune system. Front Microbiol. 2017;8:2345. https:\/\/doi.org\/10.3389\/fmicb.2017.02345.","journal-title":"Front Microbiol"},{"key":"2004_CR54","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3390\/biomedicines10010084","volume":"10","author":"L Wang","year":"2022","unstructured":"Wang L, et al. Bifidobacterium bifidum shows more diversified ways of relieving non-alcoholic fatty liver compared with bifidobacterium adolescentis. Biomedicines. 2022;10:84.","journal-title":"Biomedicines"},{"key":"2004_CR55","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/j.jhep.2023.07.005","volume":"79","author":"Q Song","year":"2023","unstructured":"Song Q, et al. Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma. J Hepatol. 2023;79:1352\u201365. https:\/\/doi.org\/10.1016\/j.jhep.2023.07.005.","journal-title":"J Hepatol"},{"key":"2004_CR56","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.aohep.2019.06.020","volume":"18","author":"L Guohong","year":"2019","unstructured":"Guohong L, Qingxi Z, Hongyun W. Characteristics of intestinal bacteria with fatty liver diseases and cirrhosis. Ann Hepatol. 2019;18:796\u2013803. https:\/\/doi.org\/10.1016\/j.aohep.2019.06.020.","journal-title":"Ann Hepatol"},{"key":"2004_CR57","doi-asserted-by":"publisher","unstructured":"Silva RSd, Mendon\u00e7a IP, Paiva IHRd, Souza JRBd, Peixoto CA. Fructooligosaccharides and galactooligosaccharides improve hepatic steatosis via gut microbiota-brain axis modulation. Int J Food Sci Nutr.\u00a02023;74:760\u2013780. https:\/\/doi.org\/10.1080\/09637486.2023.2262779.","DOI":"10.1080\/09637486.2023.2262779"},{"key":"2004_CR58","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12876-020-01194-2","volume":"20","author":"A Takai","year":"2020","unstructured":"Takai A, et al. Fructo-oligosaccharides ameliorate steatohepatitis, visceral adiposity, and associated chronic inflammation via increased production of short-chain fatty acids in a mouse model of non-alcoholic steatohepatitis. BMC Gastroenterol. 2020;20:46. https:\/\/doi.org\/10.1186\/s12876-020-01194-2.","journal-title":"BMC Gastroenterol"},{"key":"2004_CR59","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41522-023-00399-z","volume":"9","author":"J Liu","year":"2023","unstructured":"Liu J, et al. Gut microbiome determines therapeutic effects of OCA on NAFLD by modulating bile acid metabolism. NPJ Biofilms Microbiomes. 2023;9:29. https:\/\/doi.org\/10.1038\/s41522-023-00399-z.","journal-title":"NPJ Biofilms Microbiomes."},{"key":"2004_CR60","doi-asserted-by":"publisher","first-page":"108005","DOI":"10.1016\/j.celrep.2020.108005","volume":"32","author":"S Qiao","year":"2020","unstructured":"Qiao S, et al. Activation of a specific gut bacteroides-folate-liver axis benefits for the alleviation of nonalcoholic hepatic steatosis. Cell Rep. 2020;32: 108005. https:\/\/doi.org\/10.1016\/j.celrep.2020.108005.","journal-title":"Cell Rep"},{"key":"2004_CR61","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/j.cell.2016.10.043","volume":"167","author":"MS Desai","year":"2016","unstructured":"Desai MS, et al. A dietary fiber-deprived gut microbiota degrades the colonic mucus barrier and enhances pathogen susceptibility. Cell. 2016;167:1339-1353 e1321. https:\/\/doi.org\/10.1016\/j.cell.2016.10.043.","journal-title":"Cell."},{"key":"2004_CR62","doi-asserted-by":"publisher","unstructured":"Swaney MH, Kalan LR. Living in your skin: microbes, molecules, and mechanisms. Infect Immun. 2021;89. https:\/\/doi.org\/10.1128\/IAI.00695-20.","DOI":"10.1128\/IAI.00695-20"},{"key":"2004_CR63","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.21873\/invivo.13308","volume":"37","author":"D Chen","year":"2023","unstructured":"Chen D, et al. Comparing the influences of metformin and berberine on the intestinal microbiota of rats with nonalcoholic steatohepatitis. In Vivo. 2023;37:2105\u201327. https:\/\/doi.org\/10.21873\/invivo.13308.","journal-title":"In Vivo."},{"key":"2004_CR64","doi-asserted-by":"publisher","first-page":"708","DOI":"10.4254\/wjh.v10.i10.708","volume":"10","author":"W Udomsinprasert","year":"2018","unstructured":"Udomsinprasert W, Honsawek S, Poovorawan Y. Adiponectin as a novel biomarker for liver fibrosis. World J Hepatol. 2018;10:708\u201318. https:\/\/doi.org\/10.4254\/wjh.v10.i10.708.","journal-title":"World J Hepatol"},{"key":"2004_CR65","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.idcr.2016.11.008","volume":"7","author":"J Sack","year":"2017","unstructured":"Sack J, Peaper DR, Mistry P, Malinis M. Clinical implications of Paracoccus yeeii bacteremia in a patient with decompensated cirrhosis. IDCases. 2017;7:9\u201310. https:\/\/doi.org\/10.1016\/j.idcr.2016.11.008.","journal-title":"IDCases"},{"key":"2004_CR66","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1099\/mic.0.026385-0","volume":"155","author":"K Fisher","year":"2009","unstructured":"Fisher K, Phillips C. The ecology, epidemiology and virulence of Enterococcus. Microbiology. 2009;155:1749\u201357. https:\/\/doi.org\/10.1099\/mic.0.026385-0.","journal-title":"Microbiology"},{"key":"2004_CR67","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/s41467-017-00796-x","volume":"8","author":"C Llorente","year":"2017","unstructured":"Llorente C, et al. Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus. Nat Commun. 2017;8:837. https:\/\/doi.org\/10.1038\/s41467-017-00796-x.","journal-title":"Nat Commun"},{"key":"2004_CR68","doi-asserted-by":"publisher","first-page":"24","DOI":"10.15386\/cjmed-554","volume":"89","author":"OH Orasan","year":"2016","unstructured":"Orasan OH, Ciulei G, Cozma A, Sava M, Dumitrascu DL. Hyaluronic acid as a biomarker of fibrosis in chronic liver diseases of different etiologies. Clujul Med. 2016;89:24\u201331. https:\/\/doi.org\/10.15386\/cjmed-554.","journal-title":"Clujul Med"},{"key":"2004_CR69","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/s41586-019-1742-x","volume":"575","author":"Y Duan","year":"2019","unstructured":"Duan Y, et al. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature. 2019;575:505\u201311. https:\/\/doi.org\/10.1038\/s41586-019-1742-x.","journal-title":"Nature"},{"key":"2004_CR70","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/s43018-021-00251-3","volume":"2","author":"N Iida","year":"2021","unstructured":"Iida N, et al. Chronic liver disease enables gut Enterococcus faecalis colonization to promote liver carcinogenesis. Nature Cancer. 2021;2:1039\u201354. https:\/\/doi.org\/10.1038\/s43018-021-00251-3.","journal-title":"Nature Cancer"},{"key":"2004_CR71","doi-asserted-by":"publisher","unstructured":"Ali A. et al. Unraveling the draft genome and phylogenomic analysis of a multidrug-resistant Planococcus sp. NCCP-2050T: a promising novel bacteria from Pakistan. 3 Biotech. 2023;13:325. https:\/\/doi.org\/10.1007\/s13205-023-03748-z.","DOI":"10.1007\/s13205-023-03748-z"},{"key":"2004_CR72","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s12223-021-00919-4","volume":"67","author":"L Mali\u0161ov\u00e1","year":"2022","unstructured":"Mali\u0161ov\u00e1 L, et al. The first case of Planococcus glaciei found in blood, a report from the Czech Republic. Folia Microbiol. 2022;67:121\u20137. https:\/\/doi.org\/10.1007\/s12223-021-00919-4.","journal-title":"Folia Microbiol"},{"key":"2004_CR73","doi-asserted-by":"publisher","first-page":"1057829","DOI":"10.3389\/fphar.2022.1057829","volume":"13","author":"S Yu","year":"2022","unstructured":"Yu S, Ji G, Zhang L. The role of p53 in liver fibrosis. Front Pharmacol. 2022;13:1057829. https:\/\/doi.org\/10.3389\/fphar.2022.1057829.","journal-title":"Front Pharmacol"},{"key":"2004_CR74","doi-asserted-by":"publisher","unstructured":"Hunt, B. C. et al. Metabolic interplay between Proteus mirabilis and Enterococcus faecalis facilitates polymicrobial biofilm formation and invasive disease. bioRxiv. 2023.\u00a0https:\/\/doi.org\/10.1101\/2023.03.17.533237.","DOI":"10.1101\/2023.03.17.533237"},{"key":"2004_CR75","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.3748\/wjg.v19.i23.3562","volume":"19","author":"E Golinska","year":"2013","unstructured":"Golinska E, et al. Virulence factors of Enterococcus strains isolated from patients with inflammatory bowel disease. World J Gastroenterol. 2013;19:3562\u201372. https:\/\/doi.org\/10.3748\/wjg.v19.i23.3562.","journal-title":"World J Gastroenterol"},{"key":"2004_CR76","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/s41564-018-0333-1","volume":"4","author":"N Nakamoto","year":"2019","unstructured":"Nakamoto N, et al. Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis. Nat Microbiol. 2019;4:492\u2013503. https:\/\/doi.org\/10.1038\/s41564-018-0333-1.","journal-title":"Nat Microbiol"},{"key":"2004_CR77","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1084\/jem.20060227","volume":"203","author":"AJ Macpherson","year":"2006","unstructured":"Macpherson AJ, Smith K. Mesenteric lymph nodes at the center of immune anatomy. J Exp Med. 2006;203:497\u2013500. https:\/\/doi.org\/10.1084\/jem.20060227.","journal-title":"J Exp Med"},{"key":"2004_CR78","doi-asserted-by":"publisher","first-page":"7369034","DOI":"10.1155\/2023\/7369034","volume":"2023","author":"XW Sun","year":"2023","unstructured":"Sun XW, et al. Liver Microbiome in healthy rats: the hidden inhabitants of hepatocytes. Cell Microbiol. 2023;2023:7369034. https:\/\/doi.org\/10.1155\/2023\/7369034.","journal-title":"Cell Microbiol"}],"container-title":["Microbiome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40168-024-02004-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40168-024-02004-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40168-024-02004-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T23:09:28Z","timestamp":1739401768000},"score":1,"resource":{"primary":{"URL":"https:\/\/microbiomejournal.biomedcentral.com\/articles\/10.1186\/s40168-024-02004-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,14]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2004"],"URL":"https:\/\/doi.org\/10.1186\/s40168-024-02004-7","relation":{},"ISSN":["2049-2618"],"issn-type":[{"value":"2049-2618","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,14]]},"assertion":[{"value":"8 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All research was approved by the University Health Network Research Ethics Board (UHN; REB#13\u20136115-A and REB#21\u20135623) and was conducted in accordance with both the Declarations of Helsinki and Istanbul, and they were also registered with ClinicalTrials.gov (NCT0185646).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Author AO receives honoraria from Ethicon and Medtronic for speaking and teaching. EC held the Lawson Family Chair in Microbiome Nutrition Research at the University of Toronto. Other authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}